Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment
Kazuteru Hatanaka, Satoshi Yuki, Hiroshi Nakatsumi, A. Hosokawa, Michio Nakamura, Osamu Muto, T. Meguro, Ichiro Iwanaga, Yasushi Tsuji, Akinori Sato, K. Eto, Koichi Furukawa, Makoto Onodera, M. Tateyama, Yasuo Takahashi, Masayoshi Dazai, Shigeyuki Yokoyama, Takuya Honda, Hiroyuki Okuda, Masatoshi Kudo, Yuh Sakata, Yoshito Komatsu (2015). P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment. , 26, DOI: https://doi.org/10.1093/annonc/mdv233.266.
Article38 days ago172P Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV
Yoshito Komatsu, Satoshi Yuki, Hiroshi Nakatsumi, Kentaro Sawada, Kazuteru Hatanaka, Takashi Kato, T. Meguro, Michio Nakamura, Ichiro Iwanaga, Minoru Uebayashi, M. Tateyama, K. Eto, Masatoshi Kudo, K. Kato, Hiroyuki Okuda, Susumu Sogabe, T. Miyagishima, Kencho Miyashita, Naoya Sakamoto, Yuh Sakata (2015). 172P Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV. , 26, DOI: https://doi.org/10.1093/annonc/mdv523.33.
Article38 days ago2092 Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV
Hiroshi Nakatsumi, Satoshi Yuki, Yasuyuki Kawamoto, Toshiya Muranaka, Kazuteru Hatanaka, Takashi Kato, T. Meguro, Michio Nakamura, Ichiro Iwanaga, Minoru Uebayashi, M. Tateyama, Kojiro Eto, Masatoshi Kudo, Seiya Kato, Hiroyuki Okuda, Susumu Sogabe, Kencho Miyashita, Yuh Sakata, Naoya Sakamoto, Yoshihiko Komatsu (2015). 2092 Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV. , 51, DOI: https://doi.org/10.1016/s0959-8049(16)31014-0.
Article38 days ago157P Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type mCRC: Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP/HGCSG1001: updated analysis of anti-tumor efficacy
Satoshi Yuki, Yoshito Komatsu, Hiroshi Nakatsumi, Toshiya Muranaka, Y. Kobayashi, T. Miyagishima, Nobuyuki Ehira, Ichiro Iwanaga, Hiroyuki Okuda, M. Tateyama, Yasushi Tsuji, Kazuteru Hatanaka, Michio Nakamura, Masatoshi Kudo, H. Fukushima, Hiroyuki Hisai, Riichiro Abe, Naoya Sakamoto, Koji Oba, Yuh Sakata (2015). 157P Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type mCRC: Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP/HGCSG1001: updated analysis of anti-tumor efficacy. , 26, DOI: https://doi.org/10.1093/annonc/mdv523.18.
Article38 days ago2094 Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP): Updated analysis of anti-tumor efficacy
Y. Kobayashi, Satoshi Yuki, Yasuyuki Kawamoto, K Sawada, T. Miyagishima, Nobuyuki Ehira, Ichiro Iwanaga, Hiroyuki Okuda, M. Tateyama, Yasushi Tsuji, Kazuteru Hatanaka, Michio Nakamura, Masatoshi Kudo, H. Fukushima, T. Tagaki, Hiroyuki Hisai, Masahiko Koike, R. Abe, Yasushi Sakata, Yoshimichi Komatsu (2015). 2094 Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP): Updated analysis of anti-tumor efficacy. , 51, DOI: https://doi.org/10.1016/s0959-8049(16)31016-4.
Article38 days ago